Literature DB >> 14507594

Genetically engineered probiotics.

Lothar Steidler1.   

Abstract

Probiotic micro-organisms have been used for many years. Originating as food supplements, they are now most often administered orally and offer an attractive alternative for treating of intestinal disorders. A better understanding of the mechanisms by which these micro-organisms act has now opened up possibilities for designing new probiotic strains. Through genetic engineering, it is possible not only to strengthen the effects of existing strains, but also to create completely new probiotics. These need not necessarily be composed only of bacterial products but can also include elements of regulatory systems or enzymes derived from a foreign-human-source. If designed carefully and with absolute attention to biological safety in its broadest sense, the development of genetically modified probiotics has the potential to revolutionize alimentary health.

Entities:  

Mesh:

Year:  2003        PMID: 14507594     DOI: 10.1016/s1521-6918(03)00072-6

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  26 in total

1.  Ethical Discourse about the Modification of Food for Therapeutic Purposes: How Patients with Gastrointestinal Diseases View the Good, the Bad, and the Healthy.

Authors:  Krista L Harrison; Gail Geller; Patricia Marshall; Jon Tilburt; Marybeth Mercer; Margaret A Brinich; Janelle Highland; Ruth M Farrell; Richard R Sharp
Journal:  AJOB Prim Res       Date:  2012-06-19

Review 2.  Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research.

Authors:  Jens Walter
Journal:  Appl Environ Microbiol       Date:  2008-06-06       Impact factor: 4.792

3.  Multilayered genetic safeguards limit growth of microorganisms to defined environments.

Authors:  Ryan R Gallagher; Jaymin R Patel; Alexander L Interiano; Alexis J Rovner; Farren J Isaacs
Journal:  Nucleic Acids Res       Date:  2015-01-07       Impact factor: 16.971

Review 4.  Bioengineered probiotics, a strategic approach to control enteric infections.

Authors:  Mary Anne Roshni Amalaradjou; Arun K Bhunia
Journal:  Bioengineered       Date:  2013-01-17       Impact factor: 3.269

5.  Rational Design of Evolutionarily Stable Microbial Kill Switches.

Authors:  Finn Stirling; Lisa Bitzan; Samuel O'Keefe; Elizabeth Redfield; John W K Oliver; Jeffrey Way; Pamela A Silver
Journal:  Mol Cell       Date:  2017-11-16       Impact factor: 17.970

6.  Hsp65-Producing Lactococcocus lactis Prevents Antigen-Induced Arthritis in Mice.

Authors:  Guilherme Gusmao-Silva; Sarah Leão Fiorini Aguiar; Mariana Camila Gonçalves Miranda; Mauro Andrade Guimarães; Juliana Lima Alves; Angélica Thomaz Vieira; Denise Carmona Cara; Anderson Miyoshi; Vasco Ariston Azevedo; Rafael Pires Oliveira; Ana Maria Caetano Faria
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

7.  Angiotensin (1-7) delivered orally via probiotic, but not subcutaneously, benefits the gut-brain axis in older rats.

Authors:  Thomas W Buford; Yi Sun; Lisa M Roberts; Anisha Banerjee; Sujitha Peramsetty; Anthony Knighton; Amrisha Verma; Drake Morgan; Gonzalo E Torres; Qiuhong Li; Christy S Carter
Journal:  Geroscience       Date:  2020-05-26       Impact factor: 7.713

8.  Multicopy integration of heterologous genes, using the lactococcal group II intron targeted to bacterial insertion sequences.

Authors:  Helen Rawsthorne; Kevin N Turner; David A Mills
Journal:  Appl Environ Microbiol       Date:  2006-09       Impact factor: 4.792

Review 9.  Helping patients make informed choices about probiotics: a need for research.

Authors:  Richard R Sharp; Jean-Paul Achkar; Margaret A Brinich; Ruth M Farrell
Journal:  Am J Gastroenterol       Date:  2009-04       Impact factor: 10.864

Review 10.  Understanding and modulating mammalian-microbial communication for improved human health.

Authors:  Sridhar Mani; Urs A Boelsterli; Matthew R Redinbo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-23       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.